Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.60 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397505 | 1.00 | RORC (0.60) | RORCS1PR5S1PR1SLC6A4SIGMAR1 | |
| SCHEMBL15397506 | 1.00 | RORC (0.60) | RORCS1PR5S1PR1SLC6A4SIGMAR1 | |
| SCHEMBL419234 | 0.90 | RORC (0.64) | RORCS1PR5S1PR1SIGMAR1 | |
| SCHEMBL1752417 | 0.90 | RORC (0.64) | RORCS1PR5S1PR1SIGMAR1 | |
| SCHEMBL14371541 | 0.90 | RORC (0.64) | RORCS1PR5S1PR1SIGMAR1 | |
| SCHEMBL12303485 | 0.90 | RORC (0.64) | RORCS1PR5S1PR1SIGMAR1 | |
| SCHEMBL1752470 | 0.90 | RORC (0.64) | RORCS1PR5S1PR1SIGMAR1 | |
| SCHEMBL1751711 | 0.90 | RORC (0.64) | RORCS1PR5S1PR1SIGMAR1 | |
| SCHEMBL8484105 | 0.90 | RORC (0.64) | RORCS1PR5S1PR1SIGMAR1 | |
| SCHEMBL3346208 | 0.90 | RORC (0.58) | RORCS1PR5SLC6A4SIGMAR1SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | RORC 46/4885S1PR5 4056/4885S1PR1 3516/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | RORC 46/4885S1PR5 4056/4885S1PR1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.